[D-thyroxin in the therapy of type IIa and IIb hyperlipoproteinemias].
21 patients with hyperlipoproteinaemias of type IIa and IIb were treated with D-thyroxin (4 mg/die) after a placebo phase. The observed changes of the cholesterol and triglyceride level in the serum are described. Hypermetabolic and cardiac side effects did not appear in the patients. The possible sites of action of D-thyroxin in the intermediary lipid metabolism are discussed.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D003918:Dextrothyroxine / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008875:Middle Aged; D013974:Thyroxine / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D014527:Uric Acid; D003918:Dextrothyroxine; D002784:Cholesterol; D013974:Thyroxine
D-Thyroxin in der Therapie von Hyperlipoproteinämien des Typs IIa und IIb.